Ramipril in clinical studies

Czech version

Authors: J. Špinar; J. Vítovec
Published in: Kardiol Rev Int Med 2005, 7(3): 156-159

Overview

Ramipril is a long-term ACE inhibitor, widely prescribed in Europe, including Czech Republic. It is made in powers from 1,25 mg to 10 mg and in combination with hydrochlorothiazide. Its effect had been proved in mortality studies of heart failure after myocardial infarction (AIRE), secondary prevention of ischaemic heart disease (HOPE). It is proved in diabetics (MICRO HOPE), hypertonics and also in non-diabetic nephropathy. In HOPE study it led to the dicrease of the number of cerebral vascular events, myocardial infarctions and the dicreased necessity of revascularization. In epidemiologic overviews in Germany (MITRA) and Canada (QUEBEC) the patients after myocardial infarction treated with ramipril had a better prognosis than the patients treated with another ACE inhibitor. We also present the Czech experience with ramipril from 2 studies in hypertonics and from epidemiologic monitorings.

Key words:
ramipril – heart failure – myocardial infarction – hypertension – nephropathy

Sources

1. Arnold JMO, Yusuf S, Young J et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 1284-1290.

2. Backer G, Ambrosioni E, Borch-Jonsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.

3. Bultas J. Co nového v indikacích inhibitorů ACE. Kapit Kardiol 2000; 2: 20-24.

4. Cífková R. Studie HOPE a MICROHOPE. Kapit Kardiol 2001; 3: 30-31.

5. Cífková R, Horký K, Widimský J sr et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř lék 2004; 50(9): 709-22.

6. Hall AS, Murray GD, Ball SG et al. AIREX - Follow-up study of patients randomly allocated to ramipril or placebo for heart failure after acute myocardial infarction. AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497.

7. Hall AS, Winter C, Bogie SM et al. AIRE - Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.

8. Lopez-Sandon J, Swedberg K, Mc Murray J et al. Expert consensus document on angiotensin converting enzyme in cardiovascular disease. Eur Heart J 2004; 25: 1454-71.

9. Miklík R, Špinar J, Ludka O et al. Kontrola a léčba srdečního selhání při propuštění z nemocnice. 2005; Supl (4): 108.

10. Pilote J et al. Mortality after myocardial infarction – The QUEBEC study. Ann Intern Med 2004; 141(2): 102-112.

11. Spinar J, Vítovec J, Skavarilova H, Frycova K. The use of ACE inhibitors and statins by general practicioners, internists and cardiologists. J Hypertens 2004; 22(2): 312.

12. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005; 26(11): 1115-40.

13. Šmahelová A. Inhibitory angiotenzin konvertujícího enzymu v léčbě diabetika. Vnitř Lék 2003; 49: 948-951.

14. Špaček R. Inhibitory ACE v léčba a sekundární prevenci infarktu myokardu. Remedia 2002; 12: 102-107.

15. Špinar J, Hradec J, Málek I, Toman J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání. Cor et Vasa 2001; 43: K123-38.

16. Špinar J, Ludka O, Svoboda J et al. Srovnání léčby hypertenze na interní klinice FN, na interním oddělení malé nemocnice a na specializované kardiologické klinice. Kardiol Rev 2005; 7(2): 83-89.

17. Špinar J, Vítovec J (v zastoupení řešitelů studie). Ramipril v léčbě mírné až středně těžké hypertenze. Vnitř Lék 1998; 44: 332-335.

18. Špinar J, Vítovec J, Kubecová L, Pařenica J. Klinické studie v kardiologii. Praha: Grada 2001: 485.

19. Špinar J, Vítovec J, Zicha J. Hypertenze - diagnostika a léčba. Praha: Grada 1999: 228.

20. Špinar J, Vítovec J. Metabolické účinky inhibitorů ACE. Remedia 2005; 15(2): 147-53.

21. The HOPE investigators: Effects of angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. NEJM 2000; 342: 145-53.

22. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The EuroHeart Failure Survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 2: Treatment. Eur Heart J 2003; 24: 464-75.

23. Vítovec J, Špinar J. Vliv ramiprilu na metabolické, renální a srdeční funkce u hypertenze a diabetes mellitus II.typu. Vnitř Lék 1998; 44: 332-335.

24. Widimský J et al. Hypertenze. Praha: Triton 2004: 590.

25. Wienbergen for the MITRA PLUS investigators. MIR and MITRA PLUS registry. Am J Cardiol 2002; 90: 1045-49.

26. Zanchetti A for the guidelines committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-23.

Labels

Paediatric cardiology Internal medicine Cardiac surgery Cardiology

Drug eluting stents – mechanisms of action and current indications

Microcirculation disorder in chronic venous insufficiency

Hypertension and aging heart from geriatric view

Treatment of hypertrophic cardiomyopathy

Article was published in

Cardiology Review

2005 Issue 3